4-bromo-1-isopropyl-5-methyl-3-(trifluoromethyl)pyrazole

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 4-bromo-1-isopropyl-5-methyl-3-(trifluoromethyl)pyrazole
• 英文别名: 4-bromo-1-isopropyl-5-methyl-3-(trifluoromethyl)-1H-pyrazole；4-bromo-5-methyl-1-propan-2-yl-3-(trifluoromethyl)pyrazole
• 化学式: C₈H₁₀BrF₃N₂
• 分子量: 271.08
• InChiKey: ATQQXTKWOFDKJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  三氟乙酰丙酮 在 N,N-二异丙基乙胺 作用下， 以 正庚烷 、 二氯甲烷 为溶剂， 反应 15.67h， 生成 4-bromo-1-isopropyl-5-methyl-3-(trifluoromethyl)pyrazole
  参考文献：
  名称：

  WO2020173739A5

  摘要：

  公开号：

  WO2020173739A5

文献信息

• SUBSTITUTED PIPERAZINES
  申请人：Pennell Andrew M.K.

  公开号：US20080261987A1

  公开（公告）日：2008-10-23

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了一种作为CCR1受体强效拮抗剂的化合物，已经在动物炎症测试中进一步确认，这是CCR1标志性疾病状态之一。这些化合物通常是芳基哌嗪衍生物，可用于制药组合物、治疗CCR1介导疾病的方法，以及用作竞争性CCR1拮抗剂鉴定的控制物。
• COMPOUNDS FOR THE TREATMENT OF HIV
  申请人：Bondy Steven S.

  公开号：US20140142085A1

  公开（公告）日：2014-05-22

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明提供了以下式子（I）的化合物或其盐，如本文所述。本发明还提供了包括式子（I）化合物的制药组合物，制备式子（I）化合物的方法，用于制备式子I化合物的中间体以及治疗逆转录病毒感染的治疗方法，包括由HIV病毒引起的感染。
• 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS
  申请人：ChemoCentryx, Inc.

  公开号：EP1531822B1

  公开（公告）日：2009-08-05
• Compounds For the Treatment of HIV
  申请人：Gilead Sciences, Inc.

  公开号：US20180194746A1

  公开（公告）日：2018-07-12

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
• PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK
  申请人：Galapagos NV

  公开号：US20220144823A1

  公开（公告）日：2022-05-12

  The present invention discloses compounds according to Formula I: wherein R 1 , R 2 , R 3a , R 3b , Het, X and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of endocrine, nutritional, metabolic, and/or cardiovascular diseases by administering the compound of the invention.